Literature DB >> 15551732

Reduced PTEN expression is associated with poor outcome and angiogenesis in invasive ductal carcinoma of the breast.

Ji Shin Lee1, Hyung Seok Kim, Young Bog Kim, Min Cheol Lee, Chang Soo Park, Kyung Whan Min.   

Abstract

Loss of PTEN expression has been associated with advanced stages of tumor. Tumor angiogenesis is involved in tumor progression. In breast cancer, a high frequency of mutations of the PTEN locus has been reported. However, the prognostic importance of PTEN expression and its correlation with angiogenesis in breast cancer have not been well established. Formalin-fixed, paraffin-embedded tissues from 99 women with a primary diagnosis of invasive ductal carcinoma were evaluated for PTEN expression by immunohistochemical methods. The microvessel density (MVD) was also studied by immunohistochemical labeling of endothelial cells with CD34 antibody. Computerized image analysis was used to evaluate MVD. Reduced PTEN expression was seen in 27.3% of invasive ductal carcinoma. The MVD ranged from 22.0 to 197.0, with a median value of 58.5 (65.4 +/- 27.9). Reduced PTEN expression correlated with lymph node status (P < 0.01), tumor grade (P < 0.05), and tumor-node-metastasis (TNM) stage (P < 0.05). There was a statistically significant correlation between reduced PTEN expression and increased MVD (P < 0.05). The mean MVD was higher in reduced PTEN-expressive tumors, irrespective of stage, compared with normal PTEN-expressive tumors with the same stage. On multivariate analysis, only TNM stage and reduced PTEN expression correlated with survival. Our results suggest that reduced PTEN expression may be an independent prognostic indicator in patients with invasive ductal carcinoma. PTEN loss may be associated with increased tumor angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15551732     DOI: 10.1097/00129039-200409000-00004

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  15 in total

1.  Construction and expression of human PTEN tumor suppressor gene recombinant adenovirus vector.

Authors:  Qingyong Chen; Chunyou Wang; Daoda Chen; Jianying Chen; Chunfang Jiang; Hai Zheng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

Review 2.  Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.

Authors:  Leonel F Hernandez-Aya; Ana M Gonzalez-Angulo
Journal:  Oncologist       Date:  2011-03-15

3.  Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.

Authors:  L S Steelman; P M Navolanic; M L Sokolosky; J R Taylor; B D Lehmann; W H Chappell; S L Abrams; E W T Wong; K M Stadelman; D M Terrian; N R Leslie; A M Martelli; F Stivala; M Libra; R A Franklin; J A McCubrey
Journal:  Oncogene       Date:  2008-03-10       Impact factor: 9.867

4.  Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy.

Authors:  Kan Yonemori; Koji Tsuta; Chikako Shimizu; Yutaka Hatanaka; Kaoru Hashizume; Makiko Ono; Tsutomu Kouno; Masashi Ando; Kenji Tamura; Noriyuki Katsumata; Tadashi Hasegawa; Takayuki Kinoshita; Yasuhiro Fujiwara
Journal:  Med Oncol       Date:  2008-11-18       Impact factor: 3.064

5.  The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy.

Authors:  Stuti Shroff; Michael J Overman; Asif Rashid; Rachna T Shroff; Hua Wang; Deyali Chatterjee; Matthew H Katz; Jeffrey E Lee; Robert A Wolff; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Arch Pathol Lab Med       Date:  2013-11       Impact factor: 5.534

Review 6.  Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review).

Authors:  Bo-Rim Yi; Kelvin J Choi; Seung U Kim; Kyung-Chul Choi
Journal:  Int J Oncol       Date:  2012-06-20       Impact factor: 5.650

7.  PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.

Authors:  Leiping Wang; Qunling Zhang; Jian Zhang; Si Sun; Haiyi Guo; Zhen Jia; Biyun Wang; Zhimin Shao; Zhonghua Wang; Xichun Hu
Journal:  BMC Cancer       Date:  2011-06-15       Impact factor: 4.430

8.  Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.

Authors:  Ling Deng; Jie Chen; Xiao Rong Zhong; Ting Luo; Yan Ping Wang; Hui Fen Huang; Li-Juan Yin; Yan Qiu; Hong Bu; Qing Lv; Hong Zheng
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

9.  Partial PTEN deletion is linked to poor prognosis in breast cancer.

Authors:  P Lebok; V Kopperschmidt; M Kluth; C Hube-Magg; C Özden; Taskin B; K Hussein; A Mittenzwei; A Lebeau; I Witzel; L Wölber; S Mahner; F Jänicke; S Geist; P Paluchowski; C Wilke; U Heilenkötter; Ronald Simon; Guido Sauter; L Terracciano; R Krech; A von d Assen; V Müller; E Burandt
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

10.  PTEN mutation, methylation and expression in breast cancer patients.

Authors:  Hong-Yan Zhang; Feng Liang; Zhi-Ling Jia; San-Tai Song; Ze-Fei Jiang
Journal:  Oncol Lett       Date:  2013-05-08       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.